Does Rallies show 13F holders for TVTX?

Yes. Rallies tracks hedge fund and 13F ownership data for TVTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TVTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TVTX. It does not provide personalized investment advice.

TVTX (Travere Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Travere Therapeutics, Inc. Common Stock (TVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TVTX trades at $42.86 with a market cap of $3.99B and a P/E ratio of -148.83. TVTX moved +2.91% today. Year to date, TVTX is +14.12%; over the trailing twelve months it is +147.66%. Its 52-week range spans $12.91 to $48.61. Analyst consensus is strong buy with an average price target of $53.42. Rallies surfaces TVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TVTX stock?

Hedge funds tracked by Rallies that own TVTX include Viking Global, Panagora Asset, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Travere Therapeutics, Inc. Common Stock.

TVTX Key Metrics

Key financial metrics for TVTX
Metric	Value
Price	$42.86
Market Cap	$3.99B
P/E Ratio	-148.83
EPS	$-0.29
Dividend Yield	0.00%
52-Week High	$48.61
52-Week Low	$12.91
Volume	22
Avg Volume	0
Revenue (TTM)	$490.73M
Net Income	$-25.55M
Gross Margin	97.89%

Top Hedge Funds Holding TVTX

Viking Global holds 2.60M shares of TVTX, changed -10.34% as of Mar 31, 2025.
Panagora Asset holds 592.91K shares of TVTX, changed +0.95% as of Mar 31, 2026.
Centerbook Partners holds 157.12K shares of TVTX, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 12.00K shares of TVTX, changed +0.00% as of Mar 31, 2026.

Latest TVTX News

Travere Therapeutics Posts Q1 Sales Surge 64% to $124.5M with FSGS Approval — May 4, 2026
Travere’s Filspari Gains FDA Nod for FSGS, Shares Soar 34.7% — Apr 14, 2026
Travere Gains FDA Approval for FSGS Drug After 46% Proteinuria Drop — Apr 14, 2026
Vertex Achieves 52% Proteinuria Drop in Phase III, Files FDA Submission — Mar 10, 2026
Piper Sandler Lifts Travere Therapeutics Price Target to $38 with 40% Upside — Mar 10, 2026

Recent TVTX Insider Trades

ROTE WILLIAM E. sold 2.76K (~$121.43K) on May 6, 2026.
REED ELIZABETH E sold 2.08K (~$91.24K) on May 6, 2026.
Inrig Jula sold 311 (~$13.67K) on May 6, 2026.

TVTX Analyst Consensus

13 analysts cover TVTX: 0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.42.

Common questions about TVTX

Who owns TVTX stock?: Hedge funds tracked by Rallies that own TVTX include Viking Global, Panagora Asset, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Travere Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for TVTX?: Yes. Rallies tracks hedge fund and 13F ownership data for TVTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TVTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TVTX. It does not provide personalized investment advice.